Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00123565
Registration number
NCT00123565
Ethics application status
Date submitted
22/07/2005
Date registered
25/07/2005
Date last updated
21/08/2008
Titles & IDs
Public title
Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction
Query!
Scientific title
A Randomized Dose Ranging Study of Hexadecasaccharide Including Active Control, in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention (SHINE)
Query!
Secondary ID [1]
0
0
SR123781A
Query!
Secondary ID [2]
0
0
DRI5228
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SHINE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary Atherosclerosis
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Efficacy: composite of all causes of death, new myocardial infarction, or severe myocardial ischemia requiring urgent repeat target vessel revascularization within 7 days following randomization.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [1]
0
0
Safety: Major bleeding according to the criteria of Thrombolysis In Myocardial Infarction study group.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Eligibility
Key inclusion criteria
* A person with a diagnosis of acute coronary syndrome who is scheduled to undergo a PCI within 48 hours.
* A person who is of the legal age of 21, who is mentally competent, and who has signed a written informed consent
Query!
Minimum age
21
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* A person with known allergy or any contra-indication to active control.
* A person who has received heparin during more than 48 hours before inclusion in the study.
* A person treated with warfarin (oral anticoagulant).
* A person with current bleeding or recognized increased risk of bleeding or history of intracranial hemorrhage.
* A person who has had a stroke within the last 6 months.
* A person with uncontrolled hypertension despite antihypertensive therapy.
* A person with history of clinically significant reduction in blood platelets or neutrophils (white blood cells).
* A person who has laboratory evidence of significantly reduced renal function or who is dependent on renal dialysis.
* A person who has a coronary bypass performed during the previous month.
* A pregnant or nursing woman or a woman of childbearing potential (before menopause) who does not have a negative pregnancy test and does not use a reliable method of birth control.
* A person who has received any investigational treatment in the preceding month.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2007
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1257
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Sanofi-Aventis - Macquarie Park
Query!
Recruitment postcode(s) [1]
0
0
NSW 2113 - Macquarie Park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
New Jersey
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Buenos Aires
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Diegem
Query!
Country [4]
0
0
Brazil
Query!
State/province [4]
0
0
Sao Paulo
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Quebec
Query!
Country [6]
0
0
Chile
Query!
State/province [6]
0
0
Santiago
Query!
Country [7]
0
0
Czech Republic
Query!
State/province [7]
0
0
Praha
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Paris
Query!
Country [9]
0
0
India
Query!
State/province [9]
0
0
India
Query!
Country [10]
0
0
Korea, Republic of
Query!
State/province [10]
0
0
Seoul
Query!
Country [11]
0
0
Mexico
Query!
State/province [11]
0
0
Mexico
Query!
Country [12]
0
0
Netherlands
Query!
State/province [12]
0
0
Gouda
Query!
Country [13]
0
0
Poland
Query!
State/province [13]
0
0
Warszawa
Query!
Country [14]
0
0
Portugal
Query!
State/province [14]
0
0
Porto Salvo
Query!
Country [15]
0
0
Russian Federation
Query!
State/province [15]
0
0
Moscow
Query!
Country [16]
0
0
Spain
Query!
State/province [16]
0
0
Barcelona
Query!
Country [17]
0
0
Turkey
Query!
State/province [17]
0
0
Istanbul
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to test whether SR123781A is a possible treatment for patients with acute coronary syndromes (heart attack) who are scheduled to undergo a percutaneous coronary intervention (PCI) within 48 hours after inclusion in the study. Two doses of SR123781A are currently tested, each in a group of about 180 patients per group to find which is the most adequate, versus heparin and glycoprotein IIbIIIa (GPIIBIIIA) antagonist.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00123565
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ICD CSD
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT00123565
Download to PDF